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Iliotibial band syndrome is a highly prevalent and painful condition characterized by 
anterolateral knee pain from an inflamed iliotibial band, with the current standard of care being 
physical therapy. However, we lack sufficient adjunct treatment options for patients with 
refractory iliotibial band syndrome who fail physical therapy. This study will evaluate the 
efficacy and safety of using botulinum toxin type A injections into the tensor fasciae latae 
as an adjunct therapy for patients with refractory iliotibial band syndrome.  With all 
patients receiving the same physical therapy treatment, we randomized patients to the control 
group of saline injection and to the treatment group of botulinum toxin type A injection. 
Successful use of botulinum injections will lead to significant improvement in pain and function 
in patients with refractory iliotibial band syndrome and open the door for its use in other muscle 
imbalance syndromes.  
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Chapter 1 – Introduction 
Background 
Incidence and Prevalence 
Iliotibial band syndrome (ITBS) is a painful and aggravating condition commonly found 
in physically active individuals. ITBS is a syndrome of overuse and is highly prevalent amongst 
athletes and military personnel1-3. ITBS is considered to be the most common overuse injury of 
the lateral knee with incidence ranging between 2 and 12%, and higher rates noted in active 
individuals such as runners, cyclists, soccer players, and military recruits,4-6. Among cyclists, the 
prevalence of ITBS has been reported between 15-24%7. In a study on female college athletes, 
including field hockey, soccer, and basketball players, Devan et al. (2004) demonstrated ITBS to 
be the most common overuse injury of the lower extremity8. ITBS has also been noted to be a 
common cause of lateral knee pain in rowers, hockey players, triathlon runners, and skiers8-10. 
  
Anatomy 
The iliotibial band (IT band) is a fibrous sheath that runs vertically from the iliac crest, 
along the lateral aspect of the thigh, to the lateral proximal tibia. It functions as both a tendon, 
connecting bone to bone, and a ligament, connecting muscle to bone, thereby connecting and 
stabilizing a multitude of vital structures in the proximal leg. The IT band is a fibrous 
reinforcement of the tensor fasciae latae (TFL) and originates from the external lip of the iliac 
crest on the iliac tubercle. Proximally, the IT band attaches to the TFL gluteus maximus, gluteus 
minimus, and vastus lateralis and runs across the greater trochantic bursa. Distally, the IT band 
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connects to lateral femoral epicondyle, quadriceps-patella-patellar tendon complex, and the 
biceps femoris muscle tendon-fibula complex. The IT band attaches to the lateral femoral 
epicondlye via the patellar retinaculum and epicondylo-patellar ligament. The final insertion 
point of the IT band is at Gerdy’s tubercle on the anterolateral tibia2,3,11.  
One of the predominant muscles the IT band emerges from is the TFL. The TFL is a 
fusiform muscle that originates from the anterior superior iliac spine and the anterior iliac crest. 
It is enclosed between two layers of the fasciae lata and, in combination with the gluteus 
maximus, merges into the iliotibial band, serving as its attachment proximally. The TFL is an 
accessory muscle with its main role being in medial hip rotation and hip abduction, while also 
contributing to stability of the knee during flexion and extension1,5,11.  
  
Biomechanics 
The purpose of the IT band is not only to contribute to lateral knee stabilization, but also 
help coordinate movements of its associated muscles to abduct, extend, and laterally rotate the 
hip. In active flexion of the knee, the IT band sits posteriorly to the lateral femoral epicondyle 
and assists in knee flexion. In full extension, the IT band moves anterior to the lateral femoral 
epicondyle and acts as an active knee extensor. It is this motion of the IT band gliding over the 
lateral femoral epicondyle with knee flexion and extension that is the proposed mechanism for IT 





ITBS occurs from overuse and is not considered a traumatic injury. It is characterized by 
anterolateral knee pain associated with the distal IT band. However, the exact pathogenesis of 
this pain is still is unknown. As we know this is a syndrome of overuse, it is safe to assume the 
etiology of the pain is associated with increased movment of the IT band and its associated distal 
anatomy. Originally, it was thought to be a direct tendonitis due to friction irritation of the IT 
band gliding over the lateral femoral epicondlye, and was therefor perviously termed 
“iliotibialband friction syndrome”13. More recent investigation has realitivly disproved this 
theory, demonstrating that the IT band is stongly teathered to the lateral femoral epicondlye, and 
does not demonstrate sufficient movment to cause friction and inflamed distal ITB14. 
 One of the more recent predominant theories, was that of an IT band bursitis of the 
lateral femoral epicondyle bursa. This theory suggests that the increased rubbing of the IT band 
over the lateral femoral epicondyle bursa causes inflammation of the bursa and therefor pain5. 
However, flaws have also been associated with this theory. Recent cadaver, MRI, and ultrasound 
studies have illustrated that there is no directly associated bursa deep to the IT band at the lateral 
femoral epicondlye14,15. The most recent data suggest that the anteriolateral knee pain may be 
associated with vascular and innervated adipose tissue deep to the IT band, or compression at the 
lateral synovial recess14.  
While the exact pathogenesis of IT band syndrome is still unclear, we do know that the 
pathogenesis results from overuse and is associated with decreased IT band flexibility and 
signature anteriolateral knee pain. A reduction in IT band length and increase in recruitment of 
accessory muscles, such as the TFL, has been noted in patiets with IT band syndrome and is 
theorized to contribute to the pathogenesis of this syndrome1,4,5. From the current data, it is 
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reasonable to work off the hypothesis that IT band syndrome results from increased knee 
extension and flexion resulting in a reduction in length of the IT band and irritation to the 
anteriolateral knee. Risk factors for developing ITBS include intense cross training, distance 
running, cycling, decreased ITB length, and weakness in the muscles of the knee extensors, 
flexors, and hip abductors4,11,12. 
  
Diagnosis 
Patient history and physical exams are often all that are needed to make the diagnosis of 
ITBS. Characteristic anterolateral knee pain localized between the lateral femoral epicondyle and 
Gerdy’s tubercle is highly indicative for ITBS. This pain is usually brought on by repetitive 
extension and flexion exercises of the knee. Three physical exam maneuvers are commonly 
employed to diagnose ITBS; the Noble, the modified Ober, and Thomas test. These physical 
exam maneuvers, coupled with a fitting patient history, are highly indicative and oftentimes 
diagnostic for ITBS2,3,11,12. 
In the Noble test the patient lays supine and the provider flexes and extends the knee 
several times from 0-90° while applying pressure to the lateral epicondyle of the femur. Pain or 
crepitus is considered a positive Noble’s sign, which is indicative for an irritatted distal IT band. 
For the modified Ober test, the patient lies on their unaffected side with their unaffected leg 
flexed at the hip and knee. The examiner places one hand on the superior hip to stabilize the 
pelvis and the uses the other to flex the knee to 90° while keep the thigh at 0°. If the thigh fails to 
fall more than 10° from neutral, it is considered a positive modified Ober test, and in indicative 
of IT band and TFL tightness16. Finally, the Thomas test is used to measure the general 
flexibility of hip flexors including iliopsoas muscle group, the rectus femorus, gracilis, and TFL. 
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In the Thomas test, the patient lies supine and the patient flexes both of their hips and knees, 
pulling the legs as far into the torso as possible. The patient then releases and extends the 
affected leg; the test is considered positive if the patient’s posterior thigh cannot reach the table 
and indicated overall hip flexor tightness4. 
Imaging is not needed to diagnose ITBS but is often employed to rule out other knee 
pathologies such as arthritis, joint space narrowing, patellar tracking abnormalities, and fractures. 
Plain film X-rays will read as normal or benign in patients with ITBS2,3,11. MRI can be useful in 
patients with chronic ITBS, as it can demonstrate inflammation and thickening of the IT band 
with possible associated fluid buildup over the lateral epicondyle17. However, fluid build up over 
the lateral epicondyle has been demonstrated to be non-specific and non-diagnostic to ITBS15. 
MRI is also useful in chronic ITBS patients as it helps rule out other knee pathologies as a source 
of the patient’s pain, such as tendon and meniscal tears, cartilage degeneration, and cysts. 
  
Current Treatment Options  
The current standard of care for ITBS is conservative treatment that consists of rest for 
athletic activities with gradual return to activity as tolerated. This activity restriction is 
commonly coupled with physical therapy and NSAID use. Physical therapy for ITBS is generally 
focused on hip abductor and knee extensor strengthening, and ITB stretching and lengthening11. 
Although there is a wide array of specific treatment plans for acute ITBS, the most effective 
treatment regimens all involve a combination of rest, ice, physical therapy, NSAIDs2,3. For those 
who fail traditional conservative treatment of rest and physical therapy, the next steps in ITBS 
management are corticosteroid injection for symptom relief and diagnosis, and possible surgical 
release of the IT band. Surgery is considered a final line of therapy for those with refractory or 
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chronic ITBS, but is not always a viable option for patients as it comes with its own set of 
increased risks and cost3,18.  
Statement of the Problem 
While rest and physical therapy have been demonstrated to be very effective treatment 
options for acute ITBS, few good treatment options exist for those who fail physical therapy. The 
few alternate therapies available such as steroid injections or surgical release, come which come 
with their own unique set of risks and expenses. This leaves a gap in care for those patients who 
continue to have chronic pain and therefore demonstrates a need for new therapeutic options.  In 
particular, athletes and active young adults are at higher risk for developing chronic ITBS, as 
their lifestyle is not conducive to standard conservative treatment guidelines. We are in need of 
new adjunct therapies for these patients with refractory pain, who without better adjunct 
treatment options, will continue to experience pain or opt for surgical intervention that may carry 
more risks than benefits. 
Goals and Objectives 
         The purpose of our study is to investigate alternative adjunct therapies for anterolateral 
knee pain associated with ITBS. Our proposed intervention of non-surgical release of the tensor 
fasciae latae via botulinum toxin type A (BT) injection coupled with standard physical therapy 
will aid in the lengthening of the IT band and hopefully improve therapeutic outcomes. We will 
be specifically looking at self-reported knee pain improvement measured with the Anterior Knee 
Pain Scale (AKPS) as our primary outcome, as well as functional improvement and IT band 
length as secondary outcomes. Information gained from this study will lead to new insight into 
treatment options for musculoskeletal pain and adjunct treatments for ITBS and other muscle 
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imbalance syndromes. Successful use of BT injections as an adjunct treatment for ITBS will 
improve overall pain and function of patients, reduce need for surgical intervention, and reduce 
the prevalence of chronic ITBS. In addition, successful treatment of ITBS with BT will open the 
door for the use of BT in other musculoskeletal pain syndromes.  
  
Hypothesis 
         In adults with chronic ITBS, adjunct therapy of a one time .75 units BT in 4mL saline 
injection into the TFL, coupled with physical therapy, will have a significant reduction in 
anterolateral knee pain at 6 months, measured with the Anterior Knee Pain Scale, when 




Adults: Patients ages 18-55. 
Chronic ITBS: Iliotibial band syndrome for greater than 6 months, with at least one attempt of 
conservative standard of care physical therapy for greater than two months. 
Treatment Group: Patients randomized to receive a one-time .75units of BT in 4mL saline 
injection into the TFL coupled with standard of care physical therapy. 
Placebo Group: Patients randomized to receive a one-time 4mL injection of saline into the TFL 
coupled with standard of care physical therapy. 
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Anterior Knee Pain Scale (AKPS): assesses subjective symptoms as well as functional 
limitations surrounding knee pain; it is a well-validated 13 question self-assessment focused on 
anterior knee pain with a scoring scale of 0-100, 0 being no symptoms19. 
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Chapter 2 – Review of the Literature 
  
Introduction 
         A comprehensive review of the literature was conducted utilizing PubMed, Cochrane 
Library, Emabse, Scopus, Clinicaltrials.gov, and Ovid Medline.  The controlled vocabulary 
terms searched for were “iliotibial band,” “iliotibial band pain syndrome,” “botulinum toxin,” 
and “anterolateral knee pain.” For a wider look and comprehensive review, the key words 
“Botox,” “Dysport,” “knee pain,” “IT band,” “tensor fasciae latae,” “runner’s knee,” 
“patellofemoral overload syndrome,” and “iliotibial band friction syndrome” were also searched 
for. The results of this extensive search of the literature further enhance the need for this study 
while also illustrating the basis for this study’s design. 
  
Review of Empirical Studies About the Relationship Being Studied 
Iliotibial Band Syndrome 
         Iliotibial band syndrome is thought to be a syndrome of overuse. It involves weakened 
hip flexor muscles and an overactive tensor fasciae latae, with repeated movements leading to 
inflammation and pain of the distal iliotibial band1-3. In a case series study by Fredericson et al. 
(2000) the authors compared the hip abductor torque of 24 runners with ITBS to 30 control 
runners. At baseline, there was a statistically significant difference in hip abductor torque 
between the control and ITBS group (p < 0.05). The ITBS group then completed 6 weeks of 
physical therapy focused on hip abductor strengthening, at the end of which females 
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demonstrated a 34.9% increase in hip abductor torque and males a 51.4% increase in hip 
abductor torque. 22 out of 24 participants with ITBS were pain free after 6 weeks and were able 
to return to athletics4. This study supports the theory that ITBS is associated with weak abductor 
muscles, and demonstrates hip abductor strengthening to be a curtail component in treatment.  
In an observational cross-sectional study by Baker et al. (2018), 15 injured runners with 
iliotibial band syndrome were compared with 15 control runners to examine the frontal knee and 
hip kinematics in patients with iliotibial band syndrome. Data was collected on a 30-minute run 
via a three-dimensional, high-speed camera synchronized with wireless surface 
electromyography. They demonstrated that runners with iliotibial band syndrome had increased 
knee adduction and valgus alignment (P = .002, control = -1.48°, injured = 3.74°) and increased 
tensor fasciae latae muscle activation (P = .017, control = 7% maximal contraction, injured = 
11% maximal contraction)5. This study offers support to the theory that ITBS is due in part to 
weakened hip muscles and overcompensation of the tensor fasciae latae. Therefore, this 
biomechanical theory of ITBS also offers rationale to the hypothesis suggested. The hypothesis 
that inhibition of the overcompensating tensor fasciae latae, through BT injection, could optimize 
physical therapy focusing on hip abductor strengthening and IT band stretching. 
  
Botulinum Toxin in Musculoskeletal Disorders 
         Botulinum toxin works by paralyzing skeletal muscle and has recently been used 
therapeutically in a wide array of musculoskeletal disorders. Its therapeutic paralytic effects have 
been demonstrated to be safe and effective in treating disorders such as essential tremor, 
Parkinson’s freezing gait, cervical dystonia, and strabismus6-8. Botulinum toxin works by 
inhibiting the release of acetylcholine at the neuromuscular junction, causing flaccid paralysis. 
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Safety and efficacy of BT injections specifically into the TFL have been investigated in two 
studies; one for Parkinson’s freezing gate and another for cerebral palsy. Vastik et al. (2016) 
investigated the use of BT injections into the TFL for 10 Parkinson’s freezing gait patients 
compared to 10 Parkinson’s patients without freezing gait who did not receive BT injections. 
While the results did show that there was a significant decrease in freezing gait symptoms by 3 
points (p <0.001), the sample size was very small, and their method of comparison was 
questionable. Most importantly, the study showed no adverse effects from the BT injection into 
the TFL, and an increase in accessory muscle recruitment9. Brunner et al. (2000) demonstrated 
the efficacy of BT injections into the TFL for non-surgical release of the IT band in cerebral 
palsy patients with hip malrotation10. Furthermore, BT has become a popular therapeutic option 
for patients with cerebral palsy and is widely considered a safe and effective technique in 
combating this musculoskeletal disorder11. 
In Dunne and Singer (2010) investigated the mechanism and safety of BT uses in the VL 
for muscle imbalance syndrome related knee pain. Looking at the long-term effects of BT 
injections, this follow up observational study was done to examine the length of denervation of 
the vastus lateralis following BT injection. This study investigated a sample of convenience from 
subjects previously enrolled in BT for refractory anterior knee pain studies. 9 women and 1 man, 
ages 16-25, all of whom had received BT injections into the vastus lateralis for refractory 
anterior knee pain in previous clinical trials, were enrolled. All 10 patients reported ongoing 
relief of symptoms at the time of the study, but 2 did ultimately undergo surgical intervention for 
refractory anterior knee pain. Subjects underwent needle electromyography into the vastus 
lateralis to quantify muscle denervation post-injection, measured in motor unit potential (MUP). 
All 10 subjects showed a significant reduction in MUP in the injected leg compared with their 
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own control non-injected limb, with a mean MUP amplitude reduction of 49% (p=0.0005) and 
duration reduction 36% (p=0.0003). The extent of muscle abnormality and reduction in MUP 
demonstrated a dose-dependent correlation and a correlation with time sense injection12. While 
this study was a small sampled observational study, with a sample of convenience leading to a 
contributing sampling bias, it gives us insight into the long-term effects of BT injections into the 
vastus lateralis. It encouragingly demonstrates that BT injections are relatively safe and provide 
lasting effects on muscle denervation, which could be a promising therapeutic benefit. 
  
Botulinum Toxin and Knee Pain 
         Botulinum toxin has many uses and is continuing to show promise in the treatment of 
many muscle imbalance syndromes7,8,11. Recently researchers have been exploring its use in 
specific muscle imbalance syndromes of the knee and thigh, namely with patellofemoral pain 
syndrome, patellofemoral overload syndrome, and iliotibial band syndrome. These studies 
operate on the theory, that by inhibiting an overactive muscle in the leg with a BT injection, you 
will allow for more productive physical therapy and therefore a greater decrease in symptoms. 
Overall these studies have had promising results, demonstrating a general improvement in 
symptoms with virtually no adverse events or side effects noticed.  
Singer et al. (2006) was one of the first to demonstrate the utility of BT injections for 
treatment of muscle imbalance syndromes and knee pain. In this study, eight women, ages 18-40, 
with a history of chronic anterior knee pain were given BT injections ranging from 300-500 units 
into the distal portion of the vastus lateralis, followed by a 12 week at home physical therapy 
regiment. The goal of this treatment was to enhance vastus medius recruitment and improve knee 
control, which would lead to an improvement in knee pain and function. Results were examined 
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through standard CT sequence on the quad, isometric quad strength, and self-reported knee pain 
and disability (measured with the Knee Injury and Osteoarthritis Outcome scale (KOOS)). At 12 
weeks the patients demonstrated no significant increase in vastus medius cross-sectional area but 
did demonstrate a decrease in vastus lateralis cross-sectional area 12.4% (+5%) (p 5 0.05). 
Patients also demonstrated an improvement in quadriceps strength as well as knee pain and 
function improvement13. While promising, this study, with only eight female subjects, is not 
evidence enough to promote the use of BT for anterior knee pain in the general population. In 
addition, this study offered no control group, therefore we cannot exclude a placebo effect as a 
confounding variable. Due to the lack of control group, improvements in knee pain could 
possibly be contributed to physical therapy without any effect from the BT injection; further 
studies are needed to investigate this relationship. The KOOS scale was demonstrated to not be 
particularly sensitive in the population studied, as most patients were able to remain active 
throughout the study. Finally, this study had a relatively short follow-up period of 12 weeks. 
Further studies will be needed to examine not only the efficacy, but the safety of using BT 
injections long term. In conclusion, this is a promising pilot investigation, but is lacking 
sufficient data to demonstrate any true effect. 
In 2011 Singer followed up her initial investigational study from 2006 with a double 
blind, randomized, placebo-controlled crossover trial study, to examine the efficacy of BT 
injections into the vastus lateralis for patellofemoral knee pain. 24 Patients, ages 15-55, with 
patellofemoral pain syndrome, clear evidence of vastus lateralis dominance on EMG, and no 
other structural knee pathologies or injuries, were enrolled in the study. 14 patients were 
randomized to the treatment group and received 500 units BT in 4 mL saline injections into the 
vastus lateralis, and the 10 in the control group received 4 mL saline injections into the vastus 
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lateralis. The theory behind this treatment plan was that inhibition of the overcompensating VL 
would allow for more effective strengthening of the weakened vastus medius, leading to a 
correction of the biomechanical muscle imbalance thought to be the cause of these patients’ 
anterior knee pain. Both cohorts received the same physical therapy and were instructed to 
perform exercises at home twice daily. Patients were followed for 24 weeks with pain and 
function assessments at 2, 4, 6, 12, and 24 weeks using the Anterior Knee Pain Scale (AKPS). At 
the initial endpoint of 12 weeks, significant improvement in knee pain from baseline was noted 
in the BT group over the control (p <0.03). Also, at 12 weeks, 5 subjects from the control group 
elected crossover and received open-label BT injections. Statistical analysis was not performed 
on this group due to small sample size. Long term follow-up at 24 weeks demonstrated that the 
initial BT treatment group showed sustained improvement in 11 out of the 14 subjects14. Possible 
confounding variables include patient’s adherence to physical therapy, frequency of NSAID use, 
extent of previous knee injuries.  
Overall, this was a promising follow up study to Singer’s initial investigation into the use 
of BT for patellofemoral knee pain that provided an increased level of evidence through the 
double-blind placebo-controlled study design. Another promising point in this study was the long 
term follow up to 24 weeks, which helps to investigate the use of BT not only as a symptomatic 
treatment but also as a curative measured aimed at preventing the need for surgery. Although, 
much more extensive follow up with a more detailed data collection and analysis will be needed 
to support this claim. Finally, the sample size in this study was too small to make these results 
applicable to the general population. Further studies with larger populations and more thorough 
follow-up are needed14. 
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These promising studies by Singer13,14 demonstrate promise for the short-term use of BT 
in treating anterior knee pain caused by muscle imbalance syndromes. For evidence of long-term 
safety and efficacy we can look at Silbert et al. (2012). This was a follow-up retrospective study: 
46 patients from previous clinical trials and 19 patients from private medical clinics who had 
received the same treatment of a one-time injection of BT into the vastus lateralis for 
patellofemoral knee pain were surveyed, in an attempt to examine the long-term effects of this 
treatment. This study was primarily measuring self-reported symptom relief and if knee surgery 
was required post-injection. They found that a single BT treatment led to an initial improvement 
in pain and function in 57 out of 65. 44 of those 57 patients who reported initial symptom relief 
stated that they continued to have long-term treatment benefits for an average of 34 months (SD 
25) post-injection15. This study only reported the mean treatment benefit length for those who 
sustained long-term results; they did not expand upon the 8 patients who received no initial 
benefit and the 13 patients that only received short-term treatment benefits. 
The role of BT in the treatment of knee pain associated with patellofemoral syndrome has 
been supported by numerous other studies16-18. Chen et al. (2015) was a prospective case control 
study for intervention, where 12 patients with bilateral anterior knee pain associated with 
patellofemoral syndrome received BT injections into the VL of their worse knee and used their 
non-injected knee as a control. This study demonstrated a significant reduction in anterior knee 
pain assessed with the WOMAC self-reported knee pain questionnaire (p<0.05)17. With a small 
sample size and patients acting as their own control, this study offers a low level of evidence on 
its own, but offers support to the use of BT for anterior knee pain. 
While there is increasing evidence for the use of BT injections in the VL for treatment of 
knee pain associated with patellofemoral syndrome13-15,19, only one case series study has been 
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done to evaluate the safety and efficacy of botulinum toxin type A in the TFL. Stephen et al. 
(2016) used ultrasound guided botulinum toxin injection into the TFL followed by physical 
therapy in 45 patients classified as having patellofemoral overload syndrome from either ITBS or 
superolateral fat pad impingement. Significant improvement in knee pain, measured using the 
Anterior Knee Pain Scale, and in IT band length, measured via the modified Ober test was 
demonstrated in 39 out of 45 patients. Symptom improvement in this study is suggested to be 
due to reduced lateral TFL/ITB tension, leading to increased hip abductor strength via the 
inhibition of the TFL. Overall, this study illustrates the safety and possible efficacy of using 
botulinum toxin injections into the TFL as an adjunct therapy for anteriolateral knee pain caused 
by ITBS. The drawback to this study is that it is designed as a case control and all participants 
acted as their own control. Therefore, the level of empirical scientific evidence is low, and 
confounding variables and placebo effect cannot be ruled out. Furthermore, this study focused on 
the treatment of anterior knee pain categorized as “patellofemoral overload syndrome” caused by 
either ITBS or superior lateral fat pad impingement, and was not focused on the treatment of 
ITBS anterior lateral knee pain specifically. This study provides evidence that botulinum toxin 
could be a viable treatment of ITBS, as it demonstrated a reduction in knee pain and lengthening 
of the IT band, but further studies are needed to evaluate this hypothesis20.  
 
Review of Relevant Methodology 
Patient Selection 
         ITBS is a highly prevalent condition frequently seen in orthopedic sports medicine 
clinics2. Therefore, orthopedic sports medicine clinics are an optimal place to recruit participants 
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for ITBS research. In Fredericson et al. (2000), patients were recruited from an orthopedic 
runner’s injury clinic. They were chosen based on history and physical exam with the prominent 
symptoms being lateral knee pain, local tenderness over the lateral epicondyle, a positive Noble 
compression test, and the absence of any other knee injury such as effusion or tendon injury. 
Patients were excluded if they had any history of previous knee trauma, surgery, or other 
abnormal knee findings4.  The history and physical exam findings used as selection criteria for 
this study are quite specific and reliable techniques for isolating patients with ITBS, but they 
lacked the use of imaging for more definitive diagnoses. 
Baker et al. (2018) recruited patients by either referral from a local running club or 
orthopedic clinics, and utilized similar inclusion criteria at Fredericson et al. (2000) for isolating 
patients with ITBS for their study. They also relied on the Noble compression test as a key 
diagnostic factor for ITBS, and excluded patients if they had signs of any other knee injury other 
than ITBS. One inclusion criteria specific to this study was that all their participants had to run at 
least 10 miles per week before injury1. While this is a good inclusion criteria when specifically 
studying runners, it limits the patient population considerably. Inclusion criteria and recruitment 
techniques for the study being proposed will include components of these two studies, including 
the recruitment from sports medicine clinics and the utilization of the Noble test as an inclusion 
criteria.    
  
Study Design and Intervention 
         The intervention suggested in this study will be based off of Stephen et al. (2016). Their 
study protocol used a .75units ultrasound guided injection of BT in 4mL of saline into the TFL. 
The participants were then started on a physical therapy regime, and mean change in knee pain, 
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measured with the AKPS, and mean change in ITB length, measured with the modified Ober, 
were measured at 6 weeks20.  One drawback of this study was the absence of a control group. 
Therefore, we will be adapting and expanding upon their study design and incorporating the 
study design outlined in Singer et al. (2011). They employed a placebo control, double-blinded 
study design where patients were randomized into treatment group and control group. The 
treatment group received 500units of BT into their VL and the control group received the 
equivalent volume of saline injected into their VL. Primary outcome at 12 weeks analyzed 
reduction in knee pain using the AKPS. Treatment crossover was allowed at this point and 
patients were followed for 24 weeks14. From the Singer et al. 2011, we will incorporate the 
double-blind placebo control methodology, as well as their 24-week end point.  
The Noble and Thomas test will not be used as secondary outcome measures, and as 
neither have been used in previous studies involving BT injections and therefor would be 
difficult to compare to other relevant literature. In addition, and more importantly, the Noble test 
is dichotomic and not quantifiable. The test can only be considered positive or negative and has 
no way to quantifiably measure improvement. While the Thomas test can demonstrate 
quantifiable improvement, it is considered a more general test of hip flexor flexibility and is not 
specific to the IT band or TFL1-3. 
  
Data Collection Techniques  
         The primary outcome of interest is the reduction in mean knee pain measured by the 
AKPS. The AKPS is a well-validated assessment tool for self-reported knee pain, and has been 
used in many of the studies discussed previously to examine the relationship between BT 
injections and knee pain14,15,19,20. Ittenback et al. (2016) conducted a secondary analysis of 
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prospective epidemiologic data to determine the validity and reliability of the AKPS. The records 
of 414 teenage females were used for analysis of four different methods of AKPS scoring and 
analysis. All four scoring formats of the AKPS demonstrated to have a high internal consistency 
(αcoef = 0.83 to 0.91) (SE: 0.82 to 3.00), and “moderate to high criterion related validity-as 
determined by physician’s diagnosis”: 0.92 (13-item form), 0.90 (6-item form)21.  
         The modified Ober technique is a physical exam maneuver used to assess tightness of 
ITB and TFL. This physical exam maneuver is done by having a patient lay on their side, with 
hips in neutral position, knees straight, and with the leg of interest on top. The provider stands 
behind the patient, using one hand to stabilize the pelvis and keep the hips in a neutral position, 
and the other to abduct and extend the superior leg with knee at 0°, and then slowly allows the 
leg to adduct to its resting position. In this position, if the leg cannot fully adduct and remains 
above the lower knee the test is considered positive and a sign in ITB/TFL tightness1,20,22.  Reese 
and Brandy (2003) used an inclinometer to measure the degree of hip adduction or abduction of 
the leg in the Ober and modified Ober position in a study of sixty-one subjects. A horizontal leg 
was considered to be at 0°, adduction was recorded as a positive number, and abduction was 
recorded as a negative number. This study demonstrated the interclass correlation values for the 
reliability modified Ober test was 0.91, illustrating the modified Ober test is reliable assessment 
of ITB/TFL flexibility22. This method was also used in a study discussed previously by Stephen 
et al. (2016) to assess the relationship between BT injections into the TFL and ITB length. 
  
Data Analysis 
For calculating effect and sample size we will be using the study framework and results 
from Stephen et al. (2016) and Singer et al. (2011) as they are studies of similar populations 
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looking for mean change in knee pain using the AKPS as their primary outcome. Stephen et al. 
(2016) based their power calculation off changes in AKPS in a similar population studies in 
Singer et al. (2011), demonstrating that they needed a sample size of 45 to calculate an 80% 
power 95% confidence. To account for drop out 55 patients were recruited, and 45 patients 
completed the study. They used paired T-tests were used to compare pre-injection AKPS scores 
to endpoint AKPS scores20. In contrast, in Singer et al. (2011) they used unpaired T-tests to 
compare changes in AKPS scores between treatment and control group. The study being 
proposed will use a combination of the data analysis outlined in Stephen et al. (2016), using 
paired T-tests to monitor for changes in AKPS and modified Ober tests within groups, and 
Singer et al. (2011), using unpaired T-tests to illustrate mean changes in AKPS and modified 
Ober tests between groups. As these two studies are most prominent in the medical literature, 
and most similar to our outcome of interest, our study design will incorporate aspects of their 
design to allow for consistent data across studies that can be readily comparable.  
  
Safety and Monitoring of Adverse Events 
         Very few serious adverse effects have been noted in previous studies that used BT 
injections into the VL for knee pain. Stephen et al. 2016 noted two mild adverse events: one 
patient experienced increased pain after injection, and one patient had an anxiety attack the day 
after the injection, which the patient felt could have been related to the injection. The only 
adverse event in Singer et al. (2006) was injection site pain and soreness. Singer et al. (2011) 
noted injection site bruising and soreness and slight distal thigh asymmetry as an adverse event 
in their study. Finally, in Chen et al. (2015), no adverse events were reported. These studies 
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demonstrate that the intervention being proposed is relatively safe and low risk; the study design 
will reflect the risk level appropriately while being vigilant for any possible complications. 
  
Review of Confounding Variables 
         There are a few confounding variables, worthy of note, and present in this study 
including physical therapy adherence, variability in outcome measures, and demographic 
variance. While study design will attempt to control for these and minimize their effects on study 
outcome, it is important that they be acknowledged. 
  
Physical Therapy Adherence 
         It is well known that physical therapy is considered first line standard of care for ITBS, 
and in itself generally produces a reduction in patient’s pain level23,24. Therefore, it is safe to 
assume that the more adherent a patient is to the physical therapy regime in this study, the more 
likely they are to have a reduction in knee pain regardless of intervention status.  Results can also 
be impacted by the variability in instruction provided by physical therapist, and how much the 
physical therapy program must be tailored to patient’s needs. These variables will be controlled 
for as best as possible in study design, but it is important to be cognizant of the relationship 




Variability in Outcome Measurements 
         The primary outcome of interest is the mean reduction in knee pain between the treatment 
and the control group measured with the AKPS. The AKPS has been demonstrated to be a valid 
measurement tool for self-reported symptoms, and is widely used in the orthopedic community21. 
While this assessment tool has demonstrated a high degree of reliability, it is important to note 
that it is still a patient self-report of pain and therefore is inherently subjective. The secondary 
outcome of interest, mean change in IT band length, measured with the modified Ober test, 
demonstrates a slight variability in outcome measurements, as it is a modified physical exam 
technique and therefore operator dependent. Although it has been demonstrated to be a reliable 
technique to measure ITB/TFL length and has been used as a method of data collection in 
previous studies20,22, it must still be acknowledged that this measurement is user dependent and 
therefore comes with variability. 
  
Demographic Differences 
         It has been well documented in epidemiology statistics that women have higher rates of 
ITBS than men1,3,25,26. In Day and Gillet (2019) 30 asymptomatic patients (15 male, 15 female) 
ran while data were collected via motion-capture system and force platform. Females 
demonstrated a statistically significant higher ITB strain rate than in men (p<0.05)25.  In an 
observational cross-sectional study by Kim et al. (2019), authors measured ITB strain using real 
time elastography ultrasound and found an increased IT band strain with genu varum knee 
alignment when compared to normal women (4.42 ± 1.42, P = .048) and normal men 
(3.50 ± 1.04, P = .005)26. It has been suggested that it is a difference in biomechanics and hip 
muscle activation that may account for this prevalence difference between sexes1,4,25,26. This 
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demographic difference may contribute to a selection bias and influence data outcomes based 
upon the ratio of male to female participants. 
  
Conclusion 
         The exhaustive search of the medical literature presented demonstrates an ample amount 
of evidence in favor of the hypothesis and study design being proposed. Through the research 
presented above, we can see that ITBS is often associated with weak hip abductors by over 
activation of the TFL, leading to tightness and inflammation of the ITB; which is why hip 
strengthening physical therapy and lengthening of the ITB provide symptom relief1,2,4,5. It has 
also been demonstrated the BT injections have shown successful outcomes in the treatment of 
knee pain when injected into the VL for patellofemoral syndrome13-16 and into the TFL for 
superolateral fat pad impingement and ITBS20. The review of the literature supports this study’s 
proposed mechanism of action, that temporary paralysis of the TFL will allow for more effective 
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Chapter 3 – Study Methods 
Study Design 
The study being proposed will be a double-blinded, placebo-controlled, randomized 
control trial, to investigate the use of botulinum toxin type A injection into the tensor fasciae 
latae as a viable adjunct treatment for chronic refractory ITBS. 
  
Study Population and Sampling 
Patients, ages 18-50, will be recruited from orthopedic sports medicine clinics that have a 
history of chronic or refractory ITBS. Patients with ITBS will be selected on history, and 
physical exam. X-ray and MRI may be used to rule out any other structural pathology if already 
available in a patient's history.   
Patients were considered if they met the following inclusion criteria:  
1. Symptoms lasting longer than 6 months  
2.  History of previously failed physical therapy, for at least two months  
3. Pain localized to the anterolateral knee  
4. Pain worsens with strenuous athletic activity.  
Patients were excluded from the study if they met any of the following exclusion criteria:  
1. Previous surgery on injured knee  
2. Knee instability  
3. Current injury to the knee other than to the IT band (ex: patellar subluxation, tendon t
 ear, or fracture)   
4. Moderate or severe osteoarthritis 
 
32 
            
Subject Protection and Confidentiality 
         Study design will be submitted to Yale’s Institutional Review Board for approval through 
the IRES IRB system. Patient consent forms will ensure that patient’s data will not be shared 
without their consent. Forms will state that we will not share patient data or information with 
outside parties, and all data published or shared will be deidentified. Consent will allow 
researchers full access to the patients’ medical records for study research as well as patient 




         Patients will be recruited from orthopedic sports medicine and primary care sports 
medicine clinics in Connecticut either by provider referral, review of medical record, or patient 
request. Recruitment flyers will also be posted at athletic facilities, physical therapy practices, 
and orthopedic clinics throughout the greater New Haven area. All patients will undergo a 
thorough review of their medical records, as well as history and physical examination by the 
study’s lead providers to confirm patients’ eligibility. 
  
Study Variables and Measures 
The independent variable, which will be received by the treatment gorup, is the injection 
of .75 units of botulinum toxin type A (BT) in 4mL of saline into the TFL. The control group 
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will not receive the independent variable and will instead receive a placebo injection of 4mL 
saline into their TFL. Both the treatment group and the control group will receive the same 
physical therapy instruction. 
The main dependent variable, and primary outcome, is mean reduction in pain from 
baseline measured via the AKPS at 24 weeks. The AKPS is a self-reported knee pain scale that 
provides a more detailed look at knee pain in relation to patient activity and functional level. The 
AKPS will be administered at week 0, 1, 2, 4, 8, 12, and 24 to monitor the effects of treatment 
overtime. The primary outcome of interest in mean reduction in knee pain, measured with the 
AKPS, from week 0 to week 24. 
The secondary outcome of interest will be the mean change in IT band length from 
baseline. IT band length will be measured using the modified Ober test, where flexibility will be 
measured with an inclinometer. The modified Ober test is a physical exam maneuver where the 
patient lies on their unaffected side while the provider extends their injured leg with the knee in 
extension. The inclinometer is then placed on the lateral epicondyle of the femur. Abduction is 
read as a negative number, adduction read as a positive number, with true horizontal reading at 
0°. IT band length will be measured at baseline, and at 1, 2, 4, 8, 12, and 24 weeks. 
  
Physical Therapy Regime Received by Both Groups 
Physical therapy for both groups will follow standard practice guidelines for ITBS and 
will primarily consist of diffuse, lower-extremity stretching focused on the IT band, hamstring, 
gastrocnemius, and soleus. In addition, physical therapy will also include strengthening 
components focused on the hip abductors and quadriceps. Physical therapy will be conducted 
once a week by certified physical therapists at Yale Physical Therapy Centers in New Haven and 
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Milford. Physical therapy sites will be trained on study protocol and the specific rehab regiment.  
These physical therapists will be instructed to perform the same set of exercises with all patients, 
educate the them about at home exercises, and advance the them as appropriate. 
Patients will all be given a physical therapy exercise log that outlines the week's 
exercises. They will meet with the physical therapist on the first day of each new exercise log 
week so the physical therapist can instruct them on proper exercise technique. Every patient will 
be given the same set of exercises each week. The exercise difficulty will increase each week. At 
any point throughout the study, if the patient cannot tolerate the increase in difficulty or if the 
physical therapist recommends not advancing the patient, they will continue to repeat the highest 
level of difficulty tolerated until they can progress further, or the study ends.   
  
Blinding of Intervention 
To ensure continuity in technique and limit bias, the same provider will perform all 
injections. This provider will be the only unblinded member of the research team, and after 
administration of injection will not participate in further patient care, data gathering, or data 
analysis. The patient, physical therapist, and continuing care provider will be blinded to which 
treatment the patient has received. 
  
Assignment of Intervention 
Patients will be randomized into two groups of roughly 150 participants, depending upon 
recruitment, via computer generator stratification program. These randomized control and 
intervention groups will be subsequently stratified based on age, gender, weight, activity level, 
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IT band length relative to height, and baseline pain score. Random treatment allocation and 




         The initial intervention, which is the independent variable, is a one-time injection into the 
TFL. This is done under direct supervision of research staff and therefore adherence to the 
intervention will not be an issue in this study. However, the physical therapy adherence and 
activity level compliance need to be monitored. The physical therapists will fill out a patient 
adherence form that will include: how many treatment sessions were missed and a qualitative 
assessment of patient adherence and progression in physical therapy activities. Patients will 
receive a physical therapy log that outlines each day’s physical therapy activities and with a box 
to check when completed. The patients will update this log each day to mark their completion of 
that day’s activities. At the end of each week’s physical therapy log they will be asked to sign to 
attest to their log’s accuracy. This log will be shared with the research staff at each office visit to 
track patient’s adherence to physical therapy regiment. 
  
Monitoring of Adverse Events 
         No significant adverse effects were noted in any previous study of BT injections into the 
TFL or the VL. Mild adverse effects that did occur were injection sight pain, redness, and one 
anxiety attack. For these mild, but possible, adverse events we will have patients fill out a self-
reported questionnaire throughout the study. Questionnaires on adverse events will be performed 
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on the day of injection, and at each research visit. Patients will be encouraged to reach out to the 
researchers at any point in the study with whatever concern they may have. The only severe 
adverse events that are notable are infection or allergic reaction from the injection. Although, we 
consider this to be very unlikely and has not been seen as an outcome in any previous studies of 
note. For this and any other severe adverse event, we will encourage patients to seek medical 
attention promptly, document the adverse event thoroughly, and release them from the study. 
  
Data Collection 
The primary outcome of interest is mean reduction in knee pain from baseline. This will 
be measured using the AKPS and will be assessed at research office visits at week 0, 1, 2, 4, 8, 
12, and 24. The secondary outcome of interest is the mean change in IT band length from 
baseline. IT band length will be assessed through the modified Ober test and measured with an 
inclinometer at week 0, 1, 2, 4, 8, 12, and 24. Both of these data collection techniques are 
outlined in further detail above in “Study Variables and Measurments.” These data points will be 
collected at baseline and follow up office visits at Yale Physician’s Building Orthopedic Clinic 
by study provider. 
  
Sample Size Calculation 
          For the given effect size (population means of 15.00 vs. 8.60), standard deviation of 16, 
treatment group sizes of 148 and 148, and an alpha of 0.010 for a 2-tailed T-test the power is 
0.801. A Bonferoni correction was chosen correcting our alpha to 1% to correct for errors in 
sample size calculations and prevent a false positive. For this study we will need a sample size of 
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296 to discern a significant difference between treatment and placebo group analyzed with a 2-
tailed T-test. To account for an expected 10% attrition rate 330 patients will need to be enrolled. 
Sample size calculations are based on results from Singer et al. 2011 and Stephen et al. 2016. 
  
Analysis 
         Both the primary outcome of interest, reduction in knee pain from baseline, and the 
secondary outcome, change in IT band length from baseline, will be treated as continuous 
variables. These variables will be compared individually by the students paired T-test, and as a 
mean change by group with the student T-test. The random allocation of control and treatment 
groups in combination with group stratification based on possible confounding variables will 
allow for easily comparable homogenous groups. 
  
Timeline and Resources 
The Recruitment Phase is the first phase of the study that will run for one year from 
01/01/2021-12/31/2021. The Experimental Phase will overlap with the recruitment phase by six 
months and will also last one year from 07/01/2021- 06/31/2022. With the last patients will be 
enrolled in the study at the end of 2021, and the study run for 6 months, the latest patients 
enrolled will be finished with the study protocol by mid 2022. Data will be collected throughout 
the experimental phase. This will leave six months for the final analysis phase, from 07/01/2022-




         The study will be conducted at Yale Orthopedics/Sports Medicine at the Yale Physicians 
Building in New Haven, CT. The research team will include four providers. The first provider 
will be the only unblinded member of the study. This unblinded member will administer the 
injection into the TFL and will not be involved in any other aspect of research after injection 
administration. The other three providers will assist with recruitment, perform baseline 
assessment and confirm diagnosis of chronic ITBS. They will also conduct the study’s follow-up 
visits and perform the modified Ober test to measure IT band length. Physical therapists from 
different Yale physical therapy sites throughout the greater New Haven area will be needed to 
conduct physical therapy sessions with participants. Finally, a team of five research assistants 
will be needed to help with patient recruitment, enrollment, data collection and analysis. Besides 
botulinum toxin injections, equipment already available at the sports medicine clinic and 
physical therapy offices will be sufficient for study needs.  
  
Ethical Considerations 
While this study proposes a relatively safe and non-invasive procedure, there are a few 
ethical considerations to be addressed including randomized allotment of treatment and control 
groups. Both groups will receive injections, which carry their own risks of infection, injection 
site pain, bruising, and swelling. The placebo group will receive an injection without the 
possibility of treatment. While the treatment group will receive an off-label use injection. Both 
groups carry their own risks and ethical considerations, which will be carefully monitored 
throughout the study. Overall the study proposed is a relatively safe procedure with minimal risk 




Chapter 4 – Conclusion 
Advantages and Disadvantages 
Problem Definition 
         The problem, as stated, is a lack of treatment options for patients with chronic ITBS who 
fail conservative management. This is particularly common in highly active and athletic patients, 
not only because ITBS is more prevalent in these populations, but also because these patients 
often have a hard time refraining from activity long term. In an overuse injury such as ITBS, 
pain is provoked with increased activity. For those who fail traditional rest and physical therapy 
techniques their options are either to maintain their activity level and experience pain, undergo 
surgical intervention, or forever limit their activity and athletics. The goal of this study was to 
propose a new intervention that would allow patients to reduce their pain levels and avoid 
surgery, while maintaining their activity level and quality of life. 
         As athletes and active adults often have the highest rates of ITBS, because of this our 
study population will have high rates of athletes and atcive adults than represented in the general 
public. This makes the results less applicable to the general population. In addition, as ITBS is a 
syndrome of overuse, this population with the highest level of activity will presumably have the 
most severe symptoms at baseline. With a higher starting point for symptom severity, it will be 
easier to find a statistically significant reduction in symptoms. While this is not likely to cause a 
significant problem in data analysis, it is important to keep in mind the applications of this study 




Validity of Methods 
         The methods outlined in this study represent the most rigorous and detailed approach 
possible within practical limits. The study design is a randomized, double-blind, placebo-control 
trial, chosen to yield the highest level of empirical results. Treatment group allocation is done 
randomly and then stratified based on demographics and possible confounding variables to 
ensure the most homogenous groups possible for comparison. Allocating treatment allows for the 
intervention effect to be examined more precisely, by reducing allocation and selection bias. 
Patients, providers, physical therapists, and researchers were blinded to treatment allocation, 
reducing both the placebo effect and experimenter bias. 
The primary outcome of interest, mean reduction in anterior knee pain at 6 months, was 
measured with the AKPS. The drawback to using the AKPS as a tool in a placebo trial is that 
patients not receiving the intervention might believe that they are and therefore experience a 
placebo effect reduction in pain. However, patients in the intervention group that might 
experience the same phenomena should match this effect. Since the AKPS is solely self-reported 
with no additional empiric data, it comes with its own limitations. While the AKPS is inherently 
subjective as it is a self-reported pain scale, it has been demonstrated to be a valid measurement 
for anterior knee pain. The AKPS is also one of the more popular surveying tools used in 
orthopedics, and was used in multiple previous studies, making our results easily comparable to 
the relevant medical literature. 
The secondary outcome of interest, mean change in ITB length, measured with the 
modified Ober test allowed for understanding of the physiology behind ITBS. A correlation 
between increased ITB length and reduction of pain suggests a relationship between ITBS knee 
pain and ITB length. This however is not enough to demonstrate causation, but in combination 
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with the medical literature, supports the theory that ITBS associated knee pain is due in part to a 
short and tight ITB. Furthermore, this correlation suggests a mechanism for why BT injections 
into the TFL could reduce ITBS related knee pain. By paralyzing the TFL the ITB is allowed to 
relax and lengthen, leading to a reduction of inflammation and pain. 
In terms of analyzing our primary and secondary outcome data, both the paired T-test and 
unpaired T-test were utilized. The paired T-test allowed for comparison of individual data, 
comparing each participant’s baseline to their endpoint to determine if they had experienced a 
significant change in knee pain or IT band length. This helped us further explore the relationship 
between ITB length and knee pain in patients with chronic ITBS. In addition, it also helped us 
look at individual responses to either the intervention or control and break down results based on 
demographic and confounding variables for a more in-depth statistical analysis.  
The unpaired T-test was utilized to understand the mean change difference in outcome 
variables between groups. The mean change in knee pain and ITB length was calculated for each 
group and compared with the unpaired T-test to determine if there was a statistically significant 
difference in outcome between the two groups. The unpaired T-test comparing the mean 
reduction in knee pain between the control and treatment groups was considered the primary 
outcome of interest in this study. Therefore, this test determines the validity of the study’s 
hypothesis, and whether we can view BT injections into the TFL as a viable adjunct treatment 
for chronic ITBS.  
Both the paired and unpaired T-tests are highly validated techniques used to determine if 
a difference between two groups is significant. The only drawback in their utilization is the limit 
in their ability, they cannot track changes over time, analyze time to an event, or determine the 
number needed to treat. These outcomes were not addressed in our analysis as they were not a 
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part of this study’s hypothesis and not accounted for is the study design. For our purposes the T-
tests are sufficient to determine the validity of our hypothesis. 
Generalizability of Study Results 
         The results of this study hold great significance for patients suffering with chronic ITBS 
as it offers a viable adjunct treatment for their pain, avoid surgical intervention, and return to 
their level of activity/athletics without issue. The patient population in this study was 18-55 with 
chronic ITBS. As ITBS is a syndrome of overuse our study population will primarily consist of 
athletes and active adults by default. Therefore, the results of this study are easily applied to 
populations such as college athletes, military recruits, and generally active or athletics adults 
with chronic ITBS. As the study population was composed of chronic ITBS patients, and 
because physical therapy is known to be a successful initial treatment for ITBS, the results of this 
study are not necessarily applicable to all patients with ITBS. In addition, this study did not look 
at populations outside the 18-55 age range, populations with additional knee complications, or 
sedentary populations with ITBS. Therefore, the results of this study cannot be applied directly 
to these populations but can serve as a guide for future studies and treatment interventions in 
these groups. 
         Although the results of this study may not be applicable to all patients with ITBS, it does 
have further applications outside of the ITBS patient populations. Research in other muscular 
imbalance syndromes with similar pathophysiology to ITBS, in particular patella femoral 
syndrome, could benefit from the results of this study. While the results of this study may not be 
specifically generalizable to outside of ITBS, they are relevant to a wide variety of similar 
conditions. In addition, the results of this study give us more information about the safety and 





Successful use of BT to treat ITBS would leave a positive impact on clinical practice and 
ITBS treatment. Successful implementation of this strategy could reduce the number of patients 
opting for surgical intervention. Surgery comes with a greater risk of complications and a greater 
expense to the patient. Avoiding surgery would allow for an overall reduction in both risk and 
cost for the patient. BT treatment being less expensive than surgery would also offer a treatment 
option for patients with chronic ITBS that could not afford surgery, creating a treatment option 
that is more accessible to a wider population. With the possibility of more patients with chronic 
ITBS opting for BT intervention due to its minimal risk and cost, we could see a greater 
reduction in prevalence of chronic ITBS. 
BT therapy for ITBS not only allows for a viable alternative treatment for ITBS itself but 
creates an avenue for new therapies and greater understanding of various pathologies. Successful 
use of BT here would provide a basis for BT therapy in other disorders related to the IT band, 
including greater trochantic bursitis, and to other muscle imbalance disorders.  In addition to 
promising therapeutic discoveries, this study will also afford researchers a greater understanding 
of the pathology behind ITBS. As the IT band is connected in some way to almost all the major 
components of the lower limb, a deeper understanding of its biomechanics is crucial to a wide 
variety of pathologies. By inhibiting one of the IT band’s major muscle attachments we can gain 
a greater understanding of its biomechanics that could lead to more affective physical therapy 
and other treatments.  
         Finally, BT treatment for ITBS is a less risky and medically intensive procedure, 
allowing for mid-level providers such as PAs and NPs to perform this without needing physician 
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supervision. Many PAs across the country, and in a wide variety of medical specialties already 
treat and care for patients with ITBS. This treatment strategy, if proven a viable adjunct therapy 
for ITBS, could commonly be performed in outpatient orthopedic, sports medicine, and even 
primary care clinics. BT treatment will give patients and providers a greater array of noninvasive 
treatment options for refractory and chronic ITBS, leading to more autonomous treatment 





APPENDIX A: Sample HIC 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
  
Study Title: Tensor Fasciae Latae Botulinum Injections as an Adjunct Treatment for Iliotibial 
Band Syndrome 
Principal Investigator: Michael Medvecky, MD; J. Morgan Jones, PA-SII 
Funding Source: Yale University School of Medicine: Physician Associate Program 
  
Invitation to Participate and Description of Study 
          You have been invited to participate in a study to test the effects of botulinum toxin 
(Botox) injections into the tensor fasciae latae on chronic iliotibial band syndrome related knee 
pain. You have been asked to participate because you have been diagnosed with iliotibial band 
syndrome, have previously failed conservative therapy, and have had symptoms for more than 
six months. Approximately 300 patients will participate in this study. 
         Iliotibial band syndrome is a common injury of overuse seen in athletes and active 
populations. It is categorized by inflammation of the iliotibial band causing irritation and knee 
pain. The standard of care for this condition is considered to be conservative management of rest 
and physical therapy. However, many patients fail conservative therapy and develop chronic 
symptoms. For these patients the next level of management is considered to be steroid therapy 
and/or surgical release of the iliotibial band. Both of these second line therapies come with their 
own increased set of risks. 
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         This study proposes an alternate adjunct therapy for patients with chronic iliotibial band 
syndrome with the hopes of symptom reduction and to prevent the need to escalate to 
steroid/surgical therapies. Thus, producing a viable alternative therapy to improve patient’s 
symptoms and quality of life while allowing them to avoid more invasive and expensive 
therapeutic options. 
         In order to decide if you wish to participate in this study, it is important to understand the 
study’s procedure and all risks associated with it. This form provides information about study 
protocol as well as risk and benefits. A research team member will review this form with you and 
make sure you understand what will be expected of you, outline the procedure, explain all the 
risks involved, and answer any questions you may have. Once you understand the study you will 
be asked if you wish to participate, if so you will be asked to sign this form. 
Description of Procedures 
This study's purpose is to investigate the efficacy of using botulinum toxin injections into 
the tensor fasciae latae in combination with physical therapy to improve iliotibial band syndrome 
associated knee pain. Roughly 330 patients will be enrolled and then randomized into either the 
treatment group or the control group. Randomization will be done via computer generator and 
will not be based on any personal data. Neither the patient nor the research team will know what 
treatment group you have been assigned to. Patients randomized to the treatment group will 
receive a one-time injection of .75units of botulinum toxin into their tensor fasciae latae. Patients 
randomized to the placebo group will receive a one-time injection of 4mL of saline into their 
tensor fasciae latae. Both groups will be given the same physical therapy regime. The length of 
the study from injection to conclusion is 24 weeks. 
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         Participants will be expected to participate in eight total office visits. At each office visit 
we will ask participants to fill out the Anterior Knee Pain Scale (AKPS) to monitor their 
symptoms severity. In addition at every visit the research provider will perform a physical exam 
maneuver called the modified ober test, where the participant lays on their side and the flexibility 
of their IT band is measured with an inclinometer. An inclinometer is a noninvasive instrument 
placed against the leg of the patient that reads the angle at which the leg is resting. 
Visit 1- Pre-Study: Study eligibility evaluation and consent, AKPS and Modified Ober Test. 
Visit 2- Week 0: Tensor fasciae latae injection, AKPS and Modified Ober Test. 
Visit 3- Week 1: Check up with research staff, AKPS and Modified Ober Test. 
Visit 4- Week 2: Check up with research staff, AKPS and Modified Ober Test. 
Visit 5- Week 4: Check up with research staff, AKPS and Modified Ober Test. 
Visit 6- Week 8: Check up with research staff, AKPS and Modified Ober Test. 
Visit 7- Week 12: Check up with research staff, AKPS and Modified Ober Test. 
Visit 8- Week 24: Study Conclusion. Check up with research staff, AKPS and Modified Ober 
Test. 
In addition to office visits patients will be required to attend physical therapy once a 
week, and conduct at home exercises once a day. Patients will keep track of their at home 
physical therapy through a physical therapy log that will be reviewed by the research team at 
appointments to track therapy progress and adherence. Aside from physical therapy patients are 
encouraged to rest, and advance to more strenuous activity as advised by the physical therapist. 
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All study participants will be kept informed of any major study developments as they 
occur. If for any reason we find that one treatment is superior to the other during the course of 
the study, we will terminate the study and offer the superior treatment to all participants. 
Participants are encouraged to reach out to research staff if they have questions, concerns, or 
issues at any point in the trial. Patients will be able to withdraw from the study at any point with 
no penalty or consequences. 
This study and all relevant information will be listed on clinicaltrials.gov in accordance 
with national law. You are welcome to access information on this study at this site at any time. 
  
Risks and Inconveniences 
         We do not anticipate any significant risks or adverse events while participating in this 
study. The most likely adverse event will be injection site pain or bruising, this will be monitored 
for and the study will provide ice packs and NSAIDs on day of injection at patients request on 
injection day to offset this inconvenience. An unlikely but possible risk of this procedure in 
injection site infection, injections will be done with proper sterile technique to minimize this risk. 
Theoretical side effects include allergic reaction, muscle atrophy, and tendon rupture. These are 
all highly unlikely and are only theoretical risk as both botulinum toxin and saline have been 
demonstrated safe drugs and none of these adverse events have been reported in similar previous 
studies. 
Benefits 
         Patients will be offered standard of care physical therapy free of charge during their 
participation, which has been demonstrated to improve ITBS symptoms. In addition the 
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implementation of botulinum toxin may significantly decrease ITBS symptom severity and 
improve physical therapy outcomes. 
Economic Considerations 
         Patients will not be offered compensation for study participation. 
Treatment Alternatives 
         There are no study alternatives. If you do not wish to participate in the study you may 
wish to pursue treatment from another provider or continue conservative treatments on your own. 
Confidentiality and Privacy 
         All identifiable data obtained throughout the course of this study will remain confidential 
and will only be released with your permission or in accordance with state or federal law. When 
the results of this study are published, presented, or shared all data will be deidentified meaning 
no information would be related to you or reveal your identity unless permission is granted by 
you to do so. Only in cases of abuse to yourself or another, intent to harm yourself or another, or 
with certain reportable diseases would your information be mandated by law to be shared with 
proper authorities. 
         By signing this form and enrolling in this study you will allow this research committee to 
have access to your medical records including past doctors notes and previous imaging. This is 
done to ensure your safety in this study and to ensure you are an eligible candidate. The 
information from your medical history will not be shared with any outside party or published. 
The research team will deidentify all identifiable data, such as your name or birthdate, and will 
code your identity before any data from the study is shared. We will only collect data and 
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information relevant to the study protocol and your safety. The data will be stored and collected 
on an encrypted HIPPA compliant server. 
         The Yale Human Research Protection Program and the Yale Human Investigation 
Committee will have access to your personal information during the course of the study to ensure 
research compliance and participant safety. These individuals are required to maintain 
confidentiality. 
Voluntary Participation Withdrawal 
Participation in this study is completely voluntary and you may withdraw at any time. 
You are free to choose to decline this study. Declining this study will not bar you from receiving 
medical care that you are entitled to, and will not restrict you from seeking care in any way. 
However refusing to participate in this study means you will not receive possible beneficial 
treatments. 
Withdrawing from the Study 
If you do choose to enroll in this study, you are free to stop at any time. There will be no 
penalty or consequence of stopping the study. If you start the study and wish to stop, please 
simply contact a research team member by phone or email to let us know you no longer wish to 
participate. Once you withdraw your permission no new data will be collected. Data already 





Please let us know if there is anything, medical or legal, that you did not understand or 
was not explained properly in this form. Our research staff is happy to answer all of your 
questions and ensure you are fully informed before you make the decision to participate or not. 
Please take the time you need to review this information before making a decision. 
Authorization  
I have read (or someone has read to me) this form and have decided to continue to 
participate in the project described above.  Its general purposes, the particulars of involvement 
and possible hazards and inconveniences have been explained to my satisfaction.  My signature 
also indicates that I have received a copy of this consent addendum form. 
By signing this form, I give permission to the research team to access my medical record, 
collect data, and distribute data in accordance with the purposes outlined in this form. By 
refusing permission, I understand I will not be able to participate in this study. 
I willingly consent to participate in the study-specific blinded tensor fasciae latae 
injection.            
Initials: ________ Date:__________ 
  
Name of Subject:_____________________________                                                                         
Signature:___________________________________ 
Date:______________________________________                                                                                     
___________________________________________       ___________________ 





If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator. If you would like to talk with someone other than the 
researchers to discuss problems, concerns, and questions, offer input, discuss situations in the 
event that a member of the research team is not available, or if you have any questions 
concerning your rights as a research subject, you may contact the Human Investigation 




APPENDIX B: Recruitment Flyer 
  





      We are running a study to see if Botox injections can help reduce knee pain from 
chronic iliotibial band syndrome when combined with physical therapy. 
  
  
Who is Eligible? 
·   Ages 18-55 
·   Patients who have had iliotibial band syndrome for longer than 6 months, 
and have already failed physical therapy 
·   Patients who have no other knee conditions or injuries 
  
  
What will you be asked to do? 
·   Receive a one time injection into your hip of either saline or Botox 
·   Participate in once weekly physical therapy sessions and in daily at home 
physical therapy 
·   Come to a total of eight office visits over 6 months 
  
If you are interested or have any questions please contact us at: 
·   Email: investigator@yale.edu 





APPENDIX C: Sample Size Calculation 
  
Effect Size was calculated with data from Singer et al. 2011 and Stephen et al. 2016. 
These numbers were then used to calculate the estimated sample size using Power and Precision 
4 Software. 
  
Singer et al. 2011 compared BT injection into the VL to saline injections in the VL 
coupled with physical therapy for patellofemoral knee pain. In their treatment group they 
reported mean change in knee pain from baseline using the AKPS in individual categories, 
reporting a mean change in kneeling 50.5, stair walking 20.9, and squatting 30.8. These numbers 
were averaged to give a mean AKPS change in the treatment group of 33.6. The placebo group 
demonstrates a mean change in AKPS from baseline of 20.4. The difference in mean change in 
AKPS from baseline between the treatment and control group was 13.2. Using this we calculated 
the retaliate effect to be 57%. 
  
Stephen et al. 2016 examined the effects of BT injections into the TFL with physical 
therapy for ITBS knee pain, but without a control group. They reported a mean AKPS change of 
15 points with treatment. Using the relative effect from Singer et al. 2011 of 57% we calculated 
an expected effect of an 8.6 point change in the AKPS in the control group. The projected 
population mean effect of BT + physical therapy in the TFL for ITBS is a 15 point change in the 





To increase the likelihood of finding a true statistical significance in our study while 
reducing sampling error, and Bonferoni correction was done. This alters our alpha from 0.5% to 
1%, therefore increasing our sample size. Power and Precision 4 software was used to calculate 
that with a power of 80%, for a 2-tailed T-test and alpha of 1%, we would need 296 subjects to 
yield statistical significance and reject the null hypothesis. To account for an expected 10% 
attrition rate 330 patients will need to be enrolled.  
Figure 1. Sample Size Calculation  
 
 
Calculated using: Power and Precision. Version 4. Biostat, Inc. Englewood, NJ.   
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APPENDIX D: Sample Physical Therapy Log 
ITBS Physical Therapy Log  
Dear Participant, this is your exercise log for week one. Your Physical Therapist should 
review this with you on Day 1, and work through the exercises with you, to make sure you 
understand the exercises and how to perform them on your own. Please check off the box 
corresponding to the exercise and date as you preform them. You will return this sheet to the 
research office at your next appointment and will be given a new exercise log.  
Please let the research staff or Physical Therapists know if you have any questions or 
concerns.  
 
Week 1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Standing Legs Criss-cross Arms 
Overhead 3x30s 
       
Figure-4 Stretch 3x 30s        
Wall Calf Stretch 3x30s        
Foam Roll Glutes 2x 30s        
Foam Roll Hip Abductors 2x 30s        
Foam Roll IT Band 2x30s        
Clam Shell 2x10        
Side Bridge Hip Dips 2x10        
Extended Crunches 2x10        
Side Lying Hip Abduction 2x15        
Hip Hikes2x10        
Single Leg Step Down 2x10        
Standing Legs Criss-cross Arms 
Overhead 3x30s 
       
***All exercises are to be done on both sides, on your injured leg and your non-injured leg 
 
I (participant name) ____________________________ certify that I have completed the 
exercise regime above to the best of my abilities and have recorded my progress accurately.  
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